A health department spokesperson says the PBAC has not decided to cap the number of cost-effectiveness analysis submissions at 32. Yet it has decided that it can only meet its legal obligations under the Act with a cap of 32 in March. Clearly, there is a cap. The question is the basis on which it is applied. …
This circular and semantic argument ends with one conclusion - a submission cap
October 31, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
This circular and semantic argument ends with one conclusion - a submission cap
October 31, 2024 - - Latest News -
This would be the most significant change in PBS decision-making in over 30 years
October 31, 2024 - - Latest News -
'It has been both challenging and rewarding to lead Medicines Australia'
October 30, 2024 - - Latest News -
More stakeholder responses to COVID-19 pandemic response inquiry
October 30, 2024 - - Latest News -
Amplia announces capital raise to support the completion of Phase 2a ACCENT tr
October 30, 2024 - - Australian Biotech -
Priceline Pharmacy launches a refreshed brand strategy
October 30, 2024 - - Latest News -
Vaccine procurement and rollout was slow, but reduced the number of deaths
October 30, 2024 - - Latest News